Viromed Medical Appoints Prof. Dr. Michael A. Rubhausen to Medical Advisory Board

Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced the appointment of Prof. Dr. Michael A. Rubhausen to its Medical Advisory Board, effective immediately. The physicist and expert in spectroscopy will contribute his scientific knowledge in spectroscopy and materials research to support the company's research and development efforts.

Uwe Perbandt, CEO of Viromed Medical AG, expressed enthusiasm about the new appointment: "With Prof. Dr. Michael A. Rubhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work."

Prof. Dr. Rubhausen heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg, where he also serves as Managing Director. He is affiliated with the Center for Free-Electron Laser Science (CFEL). His research focuses on modern spectroscopic methods, including Raman spectroscopy and ellipsometry, which he uses to study superconductors, quantum materials, and biological and inorganic samples at large-scale research facilities such as PETRA III and FLASH. His interdisciplinary work spans over 180 publications with approximately 4,000 citations, with contributions to journals like Physical Review Letters, JACS, Angewandte Chemie, Nature Chemistry, Nature Physics, Cellular and Molecular Life Sciences, and Nature Communications. Additionally, he develops AI-supported analysis workflows for complex datasets.

The appointment comes as Viromed Medical AG continues to expand its scientific advisory capabilities. The company, listed on the stock exchange since October 2022, focuses on the development and distribution of cold plasma technology for medical applications through its wholly owned subsidiary Viromed Medical GmbH. Viromed aims to advance the use of cold plasma in medicine and capitalize on growth potential in the DACH region and beyond.

Adding a scientist of Prof. Dr. Rubhausen's caliber underscores Viromed's commitment to rigorous scientific validation of its technology. Cold plasma, an ionized gas at near-room temperature, has shown promise in medical applications such as wound healing and disinfection. By integrating expertise in spectroscopy and materials science, Viromed can better understand and optimize the interaction of plasma with biological tissues and materials, potentially leading to more effective and safer treatments.

Prof. Dr. Rubhausen's background in AI-supported data analysis is particularly relevant, as it could help Viromed interpret complex biomedical data and accelerate research outcomes. His experience at major research facilities like PETRA III and FLASH may also open avenues for advanced analytical techniques in evaluating plasma effects.

For more information about Viromed Medical AG, visit their website at www.viromed-medical-ag.de. The original press release is available at www.newmediawire.com.